--- title: "The Island of Misfit Stocks: Cash Cows and Sleepwalkers" type: "News" locale: "en" url: "https://longbridge.com/en/news/293448669.md" description: "From biotechs under DOJ investigation to asset managers quietly hitting record AUM, these unclassified market margins expose a stark divide. We dive into the noise to separate real hardware builders from those hiding behind financial engineering." datetime: "2026-07-22T09:18:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293448669.md) - [en](https://longbridge.com/en/news/293448669.md) - [zh-HK](https://longbridge.com/zh-HK/news/293448669.md) --- # The Island of Misfit Stocks: Cash Cows and Sleepwalkers Sometimes Wall Street acts like a giant lost-and-found bin. While institutional money obsesses over the same six tech giants, the margins of the market are stuffed with an absurd hodgepodge—from autonomous sidewalk bots and embattled biotechs to leveraged DRAM ETFs. This is stupid and here's why: most investors ignore these unclassified "leftovers," but amid this chaos, there are actual cash cows hiding next to companies that are just sleepwalking. Let's start with the head-scratchers. Regencell Bioscience Holdings Limited (RGC.US), a company touting traditional Chinese medicine for ADHD, disclosed in July 2026 that it is cooperating with a US DOJ investigation into its stock trading. The stock has tanked massively this year, shedding well over 60%. Meanwhile, CEO Yat-Gai is doubling down, buying up shares to reach 81% ownership. Honestly, with mounting legal costs and going-concern warnings looming, good luck with that. Over in Europe, Lakefront Biotherapeutics NV (LKFT.US) isn't doing much better. Sure, the Belgian biotech launched a EUR 50M share buyback mid-2026, but they just slashed their full-year revenue consensus to EUR 117.4M, and a key board member bolted for Sanofi. Why aren't you moving faster? Financial engineering and buybacks cannot mask clinical stagnation. By contrast, the heavy metal and manufacturing players are actually delivering. Constellium SE (CSTM.US) posted a massive Q1 2026, with total revenue jumping 24% year-over-year to USD 2.46B. They hit a record adjusted EBITDA and boldly hiked their full-year guidance. Booking multi-year supply deals with Airbus and tapping solar power for their German extrusion plants—this is how you run a real modern business. Japanese industrial titan Kawasaki Heavy Industries (KWHIY.US) is also making smart moves. Teaming up with Nvidia for a shipyard in Japan and partnering with Airbus on sub-hunting drones has given them serious momentum, backed by a trailing twelve-month (TTM) revenue approaching JPY 2.83T. While others sell hype, these giants are silently building the future. As for the tech stragglers, Serve Robotics Inc. (SERV.US) is an interesting one. The Uber spin-out saw its Q1 2026 revenue triple sequentially to USD 3M. They rolled out an edge AI conversational bot named "Maggie" and expanded from food delivery to automated laundry. But in a sharp pivot this July, management hit the brakes on aggressive expansion to focus on the productivity of their existing 2,000-robot fleet. It's about time—stop burning cash blindly and prove the unit economics actually work. Then we have the financial plumbing. WisdomTree Inc (WT.US) is quietly killing it, hitting a record USD 160.9B in AUM by mid-2026 after six straight record-breaking quarters driven by massive H1 inflows. Appointing a new head of digital assets strategy shows they are aggressively hunting for crypto upside. Meanwhile, Sprott Physical Copper Trust (SCOP.US) is sitting on over 14,800 metric tons of copper, riding the commodity wave and pushing forward its NYSE Arca listing plans. It is a straightforward, smart asset play. On the fixed income and derivatives side, First Trust Senior Rate Incom Fd II (FCT.US) is throwing in the towel on its old playbook. They slashed their monthly distribution by 16.2% and are merging into a new flexible income ETF (FFLX) by August 2026. Translation: the old strategy isn't working in this environment. And if you still want to gamble, there are tools like PROSHARES TRUST II VIX MID-TERM FUTURES (POST REV SPLIT) (VIXM.US) providing 5-month volatility exposure, or Defiance Daily Target 2X Long DRAM ETF (DRAL.US) for leveraged memory chip bets. My view? If you don't understand the underlying mechanics of these products, stay far away. This is the reality of the 2026 market margins. There are no "misfit" stocks, only lazy money. We will see who actually survives the year. _This article does not constitute investment advice._ ### Related Stocks - [RGC.US](https://longbridge.com/en/quote/RGC.US.md) - [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md) - [CSTM.US](https://longbridge.com/en/quote/CSTM.US.md) - [KWHIY.US](https://longbridge.com/en/quote/KWHIY.US.md) - [SERV.US](https://longbridge.com/en/quote/SERV.US.md) - [WT.US](https://longbridge.com/en/quote/WT.US.md) - [SCOP.US](https://longbridge.com/en/quote/SCOP.US.md) ## Related News & Research - [Serve Robotics (NASDAQ:SERV) Insider Euan Abraham Sells 1,390 Shares](https://longbridge.com/en/news/278776155.md) - [Serve Robotics (NASDAQ:SERV) CFO Sells $32,901.05 in Stock](https://longbridge.com/en/news/275052098.md) - [Serve Robotics 2025 10-K: $2.7M Revenue, $(1.63) EPS on widening losses](https://longbridge.com/en/news/278862292.md) - [Is Constellium’s 2025 Profit Surge Reshaping The Investment Case For Constellium (CSTM)?](https://longbridge.com/en/news/276241789.md) - [Grange Capital LLC Purchases New Position in Serve Robotics Inc. $SERV](https://longbridge.com/en/news/291942652.md)